Edition:
United States

Sawai Pharmaceutical Co Ltd (4555.T)

4555.T on Tokyo Stock Exchange

6,220JPY
9:54pm EDT
Change (% chg)

¥0 (+0.00%)
Prev Close
¥6,220
Open
¥6,240
Day's High
¥6,250
Day's Low
¥6,190
Volume
47,700
Avg. Vol
241,682
52-wk High
¥8,320
52-wk Low
¥5,720

Latest Key Developments (Source: Significant Developments)

Sawai Pharmaceutical announces application of IFRS
Monday, 15 May 2017 02:33am EDT 

May 15 (Reuters) - Sawai Pharmaceutical Co Ltd <4555.T> ::* Says it plans to apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.* Says IFRS effective from the annual report for fiscal year ending March 2018.  Full Article

R&I places Sawai Pharmaceutical on rating monitor with view to downgrading-R&I
Thursday, 20 Apr 2017 09:51pm EDT 

April 20 (Reuters) - Sawai Pharmaceutical Co Ltd <4555.T>:* Rating and Investment Information, Inc. (R&I) put the company on rating monitor with view to downgrading.* The company's current rating is "A-"-R&I.  Full Article

Sawai Pharma to buy Upsher-Smith Laboratories for $1.05 bln
Thursday, 20 Apr 2017 02:00am EDT 

April 20 (Reuters) - Japan's Sawai Pharmaceutical Co <4555.T>::Says to buy Upsher-Smith Laboratories for $1.05 billion.  Full Article

Yungjin Pharm signs 181.56 bln won contract with Sawai Pharmaceutical
Monday, 20 Mar 2017 05:16am EDT 

Yungjin Pharm Co Ltd <003520.KS> :Says it signed 181.56 billion won contract with Sawai Pharmaceutical Co Ltd to provide medicine.  Full Article

R&I affirms Sawai Pharmaceutical Co Ltd's rating at "A-" and announces stable outlook -R&I
Wednesday, 26 Oct 2016 02:12am EDT 

Sawai Pharmaceutical Co Ltd <4555.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I .Rating outlook stable -R&I.  Full Article

Sawai Pharmaceutical gearing up to sell generic drugs in U.S. - Nikkei<4555.T>
Thursday, 26 May 2016 03:29pm EDT 

Nikkei : Is gearing up to sell generic drugs in the U.S. - Nikkei . Expects to win FDA approval to sell generic version of cholesterol drug Pitavastatin starting between April and September 2017 - Nikkei . Also plans to have three other generics in the pipeline for FDA approval in the fiscal year ending in March 2018 - Nikkei . Pharmaceutical's move into U.S. and higher capacity likely will spur co to raise its group sales target for year ending in March 2018 - Nikkei .  Full Article

R&I affirms Sawai Pharmaceutical Co Ltd's rating at "A-" and stable outlook
Friday, 13 Nov 2015 01:00am EST 

Sawai Pharmaceutical Co Ltd:R&I affirms Sawai Pharmaceutical Co Ltd's rating at "A-" and stable outlook.  Full Article

More From Around the Web

REFILE-TABLE-Sawai Pharmaceutical-2016/17 group results

(Adds company forecast. Accounting policy for forecast is IFRS) May 15 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2017 Mar 31, 2016 Mar 31, 2018 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 132.43